TL;DR: TB-500 is a synthetic fragment linked to Thymosin Beta-4 research, not the full 43-amino-acid protein. The laboratory and animal evidence mainly concerns cell movement, blood-vessel formation and tissue repair. Human research on the recovery uses discussed online is still very limited, so the findings are preliminary rather than proof of a treatment. It is not a licensed medicine in Ireland and is prohibited in regulated sport.
What Is TB-500?
TB-500 is a synthetic peptide derived from a naturally occurring protein called Thymosin Beta-4 (Tβ4). Thymosin Beta-4 is produced throughout the body and is found in particularly high concentrations in wound fluid — the fluid that accumulates at the site of tissue damage. This natural presence in healing tissue gave researchers an early indication that the protein plays an active role in the repair process.
The full Thymosin Beta-4 protein contains 43 amino acids. TB-500 corresponds to a specific fragment of that sequence — amino acids 17 to 23 — which researchers have identified as the region responsible for most of the protein's biological activity. By isolating and synthesising this fragment, scientists have been able to study its properties in a more controlled and reproducible way.
Researchers have studied TB-500 in tissue repair, wound healing, inflammation and injury recovery. Most of that evidence comes from animal studies, not human clinical trials.
How does it work?
The primary mechanism through which TB-500 exerts its effects involves a protein called actin. Actin is one of the most abundant proteins in the human body and plays a fundamental role in cell structure and movement. For a cell to migrate — which is essential for wound healing, as repair cells must travel to damaged tissue — actin must be able to reorganise dynamically within the cell.
TB-500 binds to a molecule called G-actin (globular actin), the monomeric, unpolymerised form of actin. This binding promotes actin polymerisation — the process by which individual actin units link together into filaments — and critically, it facilitates the kind of rapid cytoskeletal reorganisation that allows cells to move efficiently. In simple terms, TB-500 appears to make repair and immune cells more mobile, helping them reach sites of injury more quickly.
Preclinical research has also examined angiogenesis — the formation of new blood vessels — and inflammatory signalling. Both are parts of wound repair, but preclinical mechanisms do not establish a benefit in people.
Researchers have noted that TB-500 operates through pathways that are distinct from those of BPC-157, another peptide widely studied for recovery and repair. BPC-157 primarily works through growth hormone receptor interactions and nitric oxide pathways. Because the two peptides act via complementary mechanisms, they are sometimes studied in combination, with researchers hypothesising an additive or synergistic effect on tissue repair outcomes.
What Does the Research Say?
TB-500 research is largely preclinical. Most findings come from cell cultures and animal studies rather than human clinical trials.
In wound healing studies conducted in rodent models, administration of Thymosin Beta-4 and its analogues, including the TB-500 fragment, has been associated with accelerated closure of skin wounds, improved re-epithelialisation (regrowth of skin cells), and reduced inflammatory markers at the wound site. One published review of the preclinical and early clinical work reported improved healing in diabetic and other animal models.
Tendon repair has been another area of interest. Research in animal models, including studies involving rat tendons, suggests that TB-500 may support the regeneration of tendon tissue following injury, potentially through its effects on fibroblast migration — fibroblasts being the cells primarily responsible for producing the collagen that forms tendon and connective tissue.
Cardiac research represents perhaps the most distinctive area of TB-500 investigation. Studies in rodent models of myocardial infarction (heart attack) have indicated that Thymosin Beta-4 may support recovery of cardiac tissue following ischaemic injury, potentially by promoting survival of cardiac cells and supporting new vessel formation in damaged heart muscle. Research published in Nature in 2004 by Deepak Srivastava and colleagues drew significant attention to this cardiac regenerative potential.
There are also equine studies in the record — TB-500 has been investigated and used in veterinary contexts, particularly in racehorses, for musculoskeletal recovery. Its use in horse racing has been regulated by sporting bodies due to its potential performance-recovery effects.
Human clinical data remains limited. A small number of Phase I and Phase II trials have examined Thymosin Beta-4, most notably for dry eye syndrome and wound healing in epidermolysis bullosa. Human trials have not validated the broader recovery claims that attract most interest. The animal findings generate hypotheses; they do not settle them.
What does this mean in Ireland?
TB-500 is not an authorised medicine in Ireland. Advertising unauthorised human medicines is prohibited; supply and import are subject to legal restrictions. Check current HPRA and Revenue guidance.
A research label or certificate of analysis does not establish safety for people or medicine authorisation.
Sport status: Thymosin-beta 4 and its derivatives, including TB-500, are named under S2.3 and prohibited at all times. See the WADA 2026 Prohibited List.
The short version
- TB-500 is a synthetic fragment of the naturally occurring protein Thymosin Beta-4, found in high concentrations in wound fluid.
- Its primary mechanism involves promoting actin polymerisation, which enhances cell migration — a key step in tissue repair and wound healing.
- TB-500 also promotes angiogenesis (new blood vessel formation) and has demonstrated anti-inflammatory effects in preclinical research.
- Animal studies show promise in wound healing, tendon repair, and cardiac recovery following injury — but human clinical trial data is very limited.
- Findings about TB-500 and BPC-157 separately do not establish the safety or efficacy of combining them.
- In Ireland, TB-500 is not a licensed medicine. It is regulated by the HPRA and prohibited in sport under WADA rules.
- The evidence base is promising but preliminary. Extrapolating animal findings directly to human outcomes is not scientifically justified at this stage.